Business & Economy · 26 views
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
Eli Lilly and Regeneron are among the first seven companies the U.S. Food and Drug Administration selected for a pilot program designed to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC has learned.
Summary
Eli Lilly and Regeneron are among the first seven companies the U.S. Food and Drug Administration selected for a pilot program designed to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC has learned. Lilly, Regeneron, Amneal , Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA's PreCheck pilot program, according to FDA spokesperson Benjamin Nichols.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Business & Economy
Continue reading recent Business & Economy coverage
- Oracle’s AI bet pays off as cloud momentum helps drive a rosier forecastContinue reading
- McClatchy Makes Deep Job Cuts to Newspapers Around the CountryContinue reading
- All the ways record-high diesel and rising gas prices are about to make your life more expensive — from commuting to grocery shoppingContinue reading
- Want Apple’s $1,999 foldable iPhone Duo? Here’s what T-Mobile, AT&T and Verizon are doing to lower the cost.Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow